Eksempler på brug af Total bilirubin på Engelsk og deres oversættelser til Dansk
{-}
-
Medicine
-
Colloquial
-
Official
-
Financial
-
Ecclesiastic
-
Official/political
-
Computer
Phosphokinase Increased total bilirubin.
The total bilirubin should be≤ 1.5 times upper limit of normal.
Total bilirubin skal være ≤ 1, 5 gange den normale øvre grænseværdi.High creatine phosphokinase Increased total bilirubin.
Høje niveauer af kreatinkinase Forøget total bilirubin.Grade 3 or 4 elevation of total bilirubin was noted in 35% 5% Grade 4.
Grad 3 eller 4 forhøjelse af total bilirubin blev noteret hos 35% 5% grad 4.Of patients had ALT elevations both> 10 times ULN and> 2 times baseline, 4% had ALT elevations> 3 times baseline, and<1% had ALT elevations> 2 times baseline together with total bilirubin> 2 times ULN and> 2 times baseline.
Af patienterne havde ALAT- stigninger både 10 gange ULN og 2 gange baseline;4% havde ALAT- stigninger 3 gange baseline; 1% havde ALAT- stigninger 2 gange baseline sammen med total- bilirubin 2 gange ULN og 2 gange baseline.Decreased total bilirubin, increased GGT, elevated plasma prolactin levels12.
Nedsat total bilirubin, øget GGT, forhøjede niveauer af plasmaprolaktin12.Micafungin treatment was associated with significant impairment of liver function(increase of ALT,AST or total bilirubin> 3 times ULN) in both healthy volunteers and patients.
Micafunginbehandling var forbundet med signifikant forværring af leverfunktion(forhøjet ALAT,ASAT eller total bilirubin> 3 gange ULN) både hos raske frivillige og hos patienter.Elevations in CK(≥ 10 X ULN), total bilirubin, reductions in phosphorus and platelet counts see below.
Stigninger i CK(≥ 10 x ULN), totalt bilirubin, fald i fosfor og antal blodplader se nedenfor.Observed changes in the laboratory parameters are: increased WBC count, basophils, eosinophils, monocytes and neutrophils, AST, ALT,LDH, total bilirubin and total protein; lowered RBC count and total protein.
Observerede forandringer i laboratorieværdier er stigning i leukocytter, basofile, eosinofile, monocytter og neutrofile, ASAT, ALAT,LDH, total bilirubin og Liver function tests Total bilirubin: 1.5 ULN AST:> ULN can be normal or< ULN if total bilirubin is> ULN.
Leverfunktionstest Total bilirubin: 1, 5 ULN AST: ULN kan være normal eller ULN hvis total bilirubin er ULN.Clinically significant laboratory abnormalities(Grades III and IV)in this group was low with elevated total bilirubin, AST and ALT reported in 2.4%, 1.6% and< 1% of patients respectively.
Klinisk signifikante afvigelser i laboratorieværdier(grad III og IV)i denne gruppe var lav med øget total bilirubin, AST og ALT rapporteret hos henholdsvis 2, 4%, 1, 6% og< 1% af patienterne.Common: elevated liver values(AST, ALT, alkaline phosphatase,direct and total bilirubin), increased serum creatinine, decreased haemoglobin, decreased haematocrit, blood potassium decreased, hypomagnesaemia, low albumin, decreased white blood cells, increased eosinophils, platelet count decreased, decreased neutrophils, increased urinary red blood cells, increased partial thromboplastin time, decreased total serum protein, increased urinary protein, increased prothrombin time, blood sodium decreased, increased urinary white blood cells and low calcium.
Forhøjede levertal(ASAT, ALAT, alkalisk phosphatase,direkte og total bilirubin), øget serum creatinin, nedsat hæmoglobin, nedsat hæmatokrit, nedsat kalium i blodet, hypomagnesiæmi, lavt albumin, reduceret antal hvide blodlegemer, øgede eosinophiltal, thrombocyttal nedsat, reduceret neutrophiltal, øget antal røde blodceller i urinen, øget partiel thromboplastintid, reduceret Hepatic reactions(e. g. mild to moderate elevations in ALT, AST,alkaline phosphatase, total bilirubin and/ or clinical hepatitis) have been reported during treatment with posaconazole.
Der har været set hepatiske reaktioner(f. eks. milde til moderate forhøjelser af ALT, AST,alkalisk phosphatase og total bilirubin og/ eller klinisk hepatitis) under behandling med posaconazol.Hepatic impairment: no clinical trials were conducted with SPRYCEL in patients with moderate to severe hepatic impairment trials excluded patients with ALT and/ or AST>2.5 times the upper limit of the normal range and/ or total bilirubin> 2 times the upper limit of the normal range.
Leverinsufficiens: der er ikke gennemført kliniske forsøg med SPRYCEL med patienter med moderat til svært nedsat leverfunktion patientermed ALAT og/ eller ASAT> 2, 5 gange den øvre normalgrænse og/ eller total- bilirubin> 2 gange den øvre normalgrænse blev ekskluderet i forsøgene.No relationships between AST(SGOT), ALT(SGPT), or total bilirubin and pemetrexed pharmacokinetics were identified.
Der er ikke fundet nogen sammenhæng mellem ASAT(SGOT), ALAT(SGPT) eller total bilirubin og pemetrexeds farmakokinetik.Clinical studies have excluded patients with alanine transaminase(ALT) and/ or aspartate transaminase(AST)> 2.5(or> 5, if related to disease)times the upper limit of the normal range and/ or total bilirubin> 1.5 times the upper limit of the normal range.
Kliniske studier har ekskluderet patienter med alanin transaminase(ALAT) og/ eller aspartat transaminase(ASAT)>2, 5(eller> 5, hvis relateret til sygdom) gange den øvre normalgrænse og/ eller total bilirubin> 1, 5 gange den øvre normalgrænse.Increased serum concentrations of total bilirubin and AAG concentrations were associated with a reduced erlotinib clearance.
Forhøjede serumkoncentrationer af total bilirubin og AAG- koncentrationer var ledsaget af en reduceret erlotinib- clearance.In a subset of 410 patients with ovarian cancer, clinically significant laboratory abnormalities occurring in clinical trials with Caelyx included increases in total bilirubin(usually in patients with liver metastases)(5%) and serum creatinine levels 5.
I en gruppe på 410 patienter med ovariecancer forekom der klinisk signifikante laboratorieabnormiteter i kliniske undersøgelser med Caelyx inklusive øgning i total bilirubin(sædvanligvis hos patienter med levermetastaser)(5%) og serum creatinin niveauer 5.Gender, presence or absence of liver metastasis at baseline,Karnofsky Performance Status, total bilirubin, serum albumin, ASAT and ALAT had no statistically significant effect on the pharmacokinetics of 5'-DFUR, 5-FU and FBAL.
Køn, tilstedeværelse eller fravær af levermetastaser ved baseline,Karnofsky Performance Status, total bilirubin, serum- albumin, ASAT og ALAT havde ingen statistisk signifikant effekt på farmakokinetikken af 5'- DFUR, 5- FU og FBAL.Repeat-dose toxicity studies performed in rats and dogs demonstrate dose-dependent adverse reactions affecting changes in bile duct histology(non-reversible within a 14 day recovery period), transient increase in transaminases,LDH, total bilirubin, total cholesterin, creatinine, urea and vomiting only in dogs.
Undersøgelser af toksiciteten ved gentagne doser, som blev gennemført på rotter og hunde, viste dosisafhængige uønskede hændelser i form af ændringer i galdegangshistologien(ikke- reversible inden for en restitueringsperiode på 14 dage), forbigående stigning i transaminaser,LDH, total bilirubin, Predefined limits of change analyses were performed for the following laboratory tests:alkaline phosphatase, total bilirubin, hematocrit, hemoglobin, neutrophils, platelet count, serum creatinine, serum glucose, serum uric acid, and WBC count.
Der blev udført prædefinerede” limits of change”- analyser for følgende laboratorietest:alkalisk fosfatase, total bilirubin, hæmatokrit, hæmoglobin, neutrofiler, blodpladetal, serumkreatinin, serumglukose, serumurinsyre og WBC- tal.Laboratory abnormalities The most frequently reported laboratory abnormality in patients receiving regimens containing REYATAZ and one ormore NRTIs was elevated total bilirubin reported predominantly as elevated indirect[unconjugated]bilirubin 84% Grade 1, 2, 3, or 4.
Laboratoriemæssige abnormaliteter Den oftest rapporterede laboratoriemæssige anormalitet hos patienter, der fik regimer indeholdende REYATAZ og én eller flere NRTIer,var forhøjet total bilirubin, primært indberettet som indirekte forhøjet[ukonjugeret]
